FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition applicable for oral administration contains an S1P receptor agonist and mannitol with the composition representing a solid dosage form. Mannitol has a particle specific surface area 1 to 7 m2/g, and the S1P receptor agonist is specified from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720), its pharmaceutically acceptable salt and FTY720-phosphate.
EFFECT: compositions under the invention are characterised by a high level of distribution uniformity of said S1P receptor agonist, and applicable for oral administration in the solid dosage form, eg in the form of a tablet or a capsule.
14 cl, 39 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| USING SIP RECEPTOR MODULATORS IN OPHTHALMOLOGY | 2006 |
|
RU2497513C2 |
| LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
| LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
